Originally Posted by
David B
Thank you, Skid, that's pretty much it in a nutshell.
And the other point I was driving at was understanding who is and what drives the customer here, what are their professional needs and wants? What are the paradigms under which they operate and what underpins their selection of a new product? What makes them start using it? Because the customer here (at the point of patronising lecturing) is not Mum and Dad, it is a specialist professional, the medical practitioner. And if you don't believe me, then you go out and try and buy a CXbladder test kit for use by yourself, and see how far you get.
From some of the comments I have read on this thread, the penny clearly hasn't dropped for some. They just don't get it. They seem to think that this product will simply fly off the shelves because it's so amazing and marvellous. It will sell it self. It's a break through! It's like some fantastic new gizmo that's just arrived in the shops and every doctor will want one. They are letting their enthusiasm, but also their ignorance about how the practice of modern medicine works, cloud their judgement. And without a thorough understanding of modern medicine, and all the players within it, and how all the bits come together how do you know if the company is doing a good job or not selling its products? How do you judge that, its business plan and strategies? How do you asses the potential of its products and the companies claims about them? How do you bench mark progress? What are the milestones that should be expected? What restrictions/rules might there be on how the product can be marketed and who administers those? Who here has even posted about that or suggested that such rules might even exist? Maybe investors are just going to rely on everything the company tells them, but I bet they wouldn't do that with Telecom or PGW or any of the other companies on the NZX. And intelligent investors don't. And has anyone here undertaken any research as to what the role of the FDA will be in relation for their hoped for growth in PEB's share price? Do they even know what the FDA is?
Anyway that's my rant for the day, and I'm making no further comments on PEB. But I'm just really frustrated that biotech has bombed so badly in this country, and a large part of that has been because of unrealistic investor expectations driven by a medical and scientific deficit in understanding to correctly asses a biotech company's potential and risk. PEB in my view is the first of the publicly listed biotech companies in NZ that actually has a shot of being successful. And I would be very disappointed if that gets cut off at the knees because sales or profit fail to meet market expectations, when those expectations were based on misplaced assumptions and ignorance in the first place.